Notable Labs

Relapsed and refractory blood cancer patients lack effective, personalized treatment options due to tumor heterogeneity and drug resistance.

An automated ex vivo drug-combination screening platform tests FDA-approved drugs on a patient's cancer cells to identify combinations that kill cancer while sparing healthy cells.

Oncologists and cancer treatment centers (and partnering pharma/biotech teams) use it to guide therapy selection for blood cancer patients and support drug discovery.